Dr. Hans Van Bronswijk has been appointed to the position of principal consultant for Parexel Consulting in its European Drug Development Practice. In this role, Dr. Van Bronswijk will advise clients on all aspects of clinical development and regulatory affairs with his in-depth knowledge of drug development and European Union (EU) regulatory procedures.

Dr. Van Bronswijk served on the Dutch Medicines Evaluation Board (MEB) for nine years as head of clinical assessment and was the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) member representing The Netherlands for six years. Dr. Van Bronswijk’s experience also includes various positions within Novartis, most recently as global head of regulatory affairs for the transplantation and immunology business unit.

“We expect that Parexel clients will benefit from Dr. Van Bronswijk’s internationally recognized drug development expertise and his unique combination of pan-European regulatory, medical, scientific, and pharmaceutical industry experience,” said Dr. Alberto Grignolo, corporate vice president, Parexel Consulting. “This appointment reinforces our leadership in helping clients achieve successful international product registrations, clinical and manufacturing performance excellence, and product safety.”